RxDoctor Payments DataLook up a doctor →

David Strobl

Cardiovascular Disease · Lansing, MINPI 1861490658

Payments from drug & device makers

$945,872in general payments, 2019–2025

Across 739 payments — averaging $1279.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$502K
  • Amarin Pharma, Inc.$165K
  • Kowa Research Institute, Inc.$108K
  • Esperion Therapeutics, Inc.$101K
  • Sanofi-aventis U.S. LLC$40K
  • Kowa Pharmaceuticals America, Inc.$23K
  • plus $6K from 4 others

What the payments were for

  • Consulting fees$35,6108%
  • Speaking & faculty fees$379,80085%
  • Travel & lodging$19,4724%
  • Food & beverage$9,7452%
  • Education$510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$945,872 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab121$74,087
Praluent PenAlirocumab25$14,521
VascepaIcosapent Ethyl12$7,671
Ezetimibe79$2,038
Rosuvastatin Calcium81$1,329
Atorvastatin Calcium14$340
Amlodipine Besylate14$69

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →